Ring Chromosome 14 Syndrome — Comprehensive Research Report

Prepared: 2026-08-28 · Target: Ring_Chromosome_14 · MONDO:0014708 Scope: disease-knowledge-base curation input (dismech schema sections 1–15)

Snippet-verification caveat. Several quotations below were extracted from full-text HTML/PDF via automated fetch and summarization. Before any of these is used as an evidence snippet: in kb/disorders/Ring_Chromosome_14.yaml, it must be re-verified against a just fetch-reference PMID:… cache — just count-verified-snippets / just validate-references is the gate, not this report. Quotes I am confident are verbatim complete abstracts (Zollino 2012 PMID:22579566→22564756, Bershteyn 2014 PMID:24413397) are marked [abstract-verbatim]. Everything else is marked [verify].

1. Disease Information

Overview

Ring chromosome 14 syndrome (r(14) syndrome) is an ultra-rare constitutional chromosomal disorder in which one copy of chromosome 14 is circularized after breakage in the short and long arms with end-to-end reunion, usually with loss of the 14q terminal segment. It is defined clinically by the near-obligate combination of early-onset, drug-resistant epilepsy, moderate-to-severe intellectual disability with disproportionate language impairment, postnatal microcephaly, a recognizable but subtle facial gestalt, retinal pigmentary abnormalities, and increased susceptibility to respiratory infection.

The syndrome's defining puzzle — and the reason it is mechanistically interesting rather than merely a contiguous-gene deletion — is that individuals with linear (non-ring) 14q terminal deletions of comparable size do not develop the refractory epilepsy or the retinal changes. The ring configuration itself, not simply the deleted gene content, appears to be pathogenic (Vaisfeld et al., Epilepsia 2021, PMID:33205446).

Key identifiers

Source: MedGen 419284; ORDO via OLS4; OMIM 616606.

Synonyms

• Ring 14 syndrome; Ring14 syndrome; r(14) syndrome; RC14 syndrome
• Ring chromosome 14
• Chromosome 14 ring
• Ring 14
• (Historic/imprecise) "14q ring syndrome"

Do not conflate with: 14q terminal deletion syndrome (linear del(14)(q32.3qter)) or 14q11.2 microdeletion syndrome. These are separate MONDO concepts, and the whole point of the Vaisfeld 2021 analysis is that the ring and linear forms are phenotypically dissociable.

Data provenance character

Essentially all published knowledge is case-level and aggregated from small series — there is no population EHR-derived cohort of meaningful size. The largest coherent clinical datasets are:

• Zollino et al. 2012, own series of 27 patients plus literature review (PMID:22564756)
• Giovannini et al. 2013, 22 patients with EEG phenotyping (PMID:24116895)
• The Ring14 International clinical database (~54 patients; genetics, growth, neurology, comorbidities, therapies) — ring14.org
• The 2017 ad hoc task-force guideline, consensus over the above (PMID:28399883 / PMC5387247)

EHR-derived signal exists but is thin: Barbour et al. (Epilepsia 2024, PMID:38795333) attempted incidence estimation for 28 rare epilepsies from NYC EHR text search and explicitly noted that "data were limited for" ring chromosome 14 and similar "genetic epilepsies with nonspecific clinical features" [verify].

2. Etiology

Primary cause

A de novo structural chromosomal rearrangement: chromosome 14 forms a ring, requiring two breakpoints — one in the short arm (an acrocentric, gene-poor p arm) and one in the long arm — followed by fusion of the broken ends and loss of the intervening terminal material.

Zollino et al. 2012 quantified the molecular spectrum in 27 patients [abstract-verbatim]:

"In our own sample of patients the ring was complete, with no apparent loss of chromosome material, in 6/27 cases, while it showed a small terminal deletion, varying in size from 0.3 to 5 Mb, in the other 21. In two of these a cryptic 14q duplication of 2.5 and 9.7 Mb, respectively, proximal to the deleted segment, was also identified. Deleted rings were 75% paternal and 25% maternal in origin. UPD (14) was excluded in all cases." — Zollino M, Ponzi E, Gobbi G, Neri G. Eur J Med Genet 2012;55:374–380. PMID:22564756, DOI:10.1016/j.ejmg.2012.03.009

Three points from this are curation-critical:

1. ~22% of rings are "complete" — cytogenetically visible ring, no detectable copy-number loss on array. These patients still have the syndrome. Copy-number loss is therefore not necessary for the phenotype.
2. Parental origin is skewed paternal (3:1) for deleted rings.
3. UPD(14) is excluded — so neither Temple syndrome nor Kagami–Ogata imprinting mechanisms are operating here (an important differential, since chromosome 14 carries the DLK1-MEG3 imprinted domain at 14q32.2).

Multiple ring-formation mechanisms are described generally for ring chromosomes (Guilherme et al., BMC Med Genet 2011, PMID:22151179): breaks in both arms with end-to-end reunion; a break in one arm fusing to the opposite subtelomere; subtelomere–subtelomere fusion; and pure telomere–telomere fusion (which yields a complete ring with no loss).

Risk factors

Genetic risk factors. There is no known heritable susceptibility. The rearrangement is sporadic. There is no reported association with parental age, and no recurrent breakpoint-flanking segmental duplication architecture has been established (unlike recurrent microdeletion syndromes). The paternal-origin skew is the only reproducible parent-of-origin signal.

Modifier candidates (hypothesis-level, not established): - The size of the terminal deletion (0.3–5 Mb) modifies which 14q32.33 genes are hemizygous — most consequentially the IGH locus (immune phenotype) and PACS2 (epilepsy candidate). - The degree of ring mitotic instability (see §6) plausibly modifies severity, including growth failure and possibly epileptogenicity, but this has never been prospectively correlated with outcome. - Presence of a cryptic proximal 14q duplication (2/27 in Zollino's series) adds a second dosage lesion.

Environmental risk factors. None identified. No teratogen, exposure, occupational, maternal-nutritional, or infectious risk factor has been associated with ring chromosome formation in humans. Ionizing radiation and clastogens can produce ring chromosomes somatically in vitro and in irradiated individuals, but no epidemiological link to constitutional ring 14 exists. Treat this as "no evidence," not "no association."

Protective factors. None identified — genetic or environmental. Not applicable to a de novo structural event.

Gene–environment interaction. No established GxE. The one arguably interaction-shaped observation is that infection burden interacts with the underlying immune lesion: hemizygosity of the 14q32.33 immunoglobulin heavy-chain locus plus altered IgG glycosylation (§6) is thought to convert ordinary respiratory pathogen exposure into recurrent/severe pneumonia, which the 2017 guideline names as the leading cause of adult death.

3. Phenotypes

3.1 Neurological — epilepsy (the cardinal feature)

Frequency: ~100%. Giovannini et al. 2013 (PMID:24116895), 22 patients:

"The incidence of epilepsy in patients with r(14) syndrome is virtually 100%, characterized by early onset, polymorphic seizures, and drug-resistant seizures." [verify]

Guideline consensus (PMC5387247) [verify]:

"All individuals with r(14) syndrome suffer from epilepsy, which is drug resistant in most cases." Onset "usually occurs in the first months of life."

EEG (Giovannini 2013; guideline) [verify]: slow, unstructured/disorganized background in both wake and sleep; generalized bursts of slow, large, asynchronous waves in frontal and posterior regions; multifocal spikes; complex spike-and-wave over occipital regions; focal spikes with secondary generalization. EEG severity negatively correlated with cognitive development — a curation-relevant causal claim (epileptic activity → cognitive outcome, not merely co-occurring).

Quality-of-life impact: dominant. Seizure burden, seizure-related injury risk, sleep disruption, and caregiver vigilance are the primary drivers of family burden (SanInocencio et al. 2026, below).

3.2 Neurodevelopmental / cognitive / behavioral

Behavior disorders were assigned by Zollino to the 14q32 region (haploinsufficiency mechanism) [abstract-verbatim].

3.3 Growth and nutrition

Growth failure is the classical "ring syndrome" phenotype (Kosztolányi) attributed to ring mitotic instability rather than to deleted gene content — see §6.

3.4 Craniofacial

The facial gestalt is real but subtle; Vaisfeld 2021 cautions [verify]: "it is very difficult to diagnose any one of the reviewed conditions based on a gestaltic impression."

Guideline description [verify]: "long and sometimes asymmetrical face, full cheeks, large forehead, hypoplastic supraorbital ridges with horizontal eyebrows, strabismus, apparent hypertelorism" — and importantly, "All these features have been reported only in patients with r(14) syndrome carrying a long arm terminal deletion of at least 650 kb."

Case-report-level features (Meza-Espinoza 2024, PMID:39020403) [verify]: prominent narrow forehead, sparse short eyebrows, palpebral ptosis, horizontal palpebral fissures, broad nasal bridge, prominent nasal tip, flat philtrum, hypertelorism, midfacial hypoplasia, thin upper lip, crowded teeth, ogival (high-arched) palate, retrognathia, wide neck.

HPO set: HP:0000316 Hypertelorism · HP:0000494 Downslanted palpebral fissures · HP:0000286 Epicanthus · HP:0005280 Depressed nasal bridge · HP:0000457 Depressed nasal ridge · HP:0000463 Anteverted nares · HP:0000369 Low-set ears · HP:0000218 High palate · HP:0000470 Short neck · HP:0005469 Flat occiput · HP:0000268 Dolichocephaly · HP:0000581 Blepharophimosis · HP:0000508 Ptosis · HP:0000347 Micrognathia · HP:0000219 Thin upper lip vermilion · HP:0000678 Dental crowding · HP:0000319 Smooth philtrum · HP:0007874 Almond-shaped palpebral fissure.

Dental management has its own literature: Ivanoff et al., Folia Med 2023, PMID:36855970 — "what the dentist should know to manage children with r(14) effectively."

3.5 Ophthalmological

Zollino 2012 [abstract-verbatim]: ocular abnormalities "consisting mainly of abnormal retinal pigmentation, but also retinitis pigmentosa, strabismus, glaucoma, and abnormal macula."

Guideline [verify]: "myopia, strabismus, cataracts, maculopathy, optic nerve damage, glaucoma and anomalies in retinal pigmentation," plus "microphtalmia and colobomas."

Vasconcelos et al., Ophthalmic Genet 2019 (PMID:31755799) documented an 11-year-old with macular yellow dots on multimodal imaging, arguing for routine ophthalmologic surveillance [verify].

HPO: HP:0000580 Pigmentary retinopathy (annotated "Occasional" in HPOA) · HP:0000510 Retinitis pigmentosa · HP:0007754 Macular dystrophy · HP:0000486 Strabismus · HP:0000545 Myopia · HP:0000518 Cataract · HP:0000501 Glaucoma · HP:0000612 Iris coloboma · HP:0000568 Microphthalmia · HP:0000648 Optic atrophy · HP:0000505 Visual impairment.

Curation note: GARD states retinal abnormalities are "typically not affecting vision." The retinal phenotype is a diagnostic marker more than a functional burden in most patients — worth capturing as a notes distinction rather than assuming visual impairment.

3.6 Immune / infectious

This is the leading cause of adult mortality — "Infections are one of the worse prognostic factors and the main cause of death in adulthood" [verify].

3.7 Musculoskeletal, GI, other

• Scoliosis (HP:0002650) — part of the defining gestalt; assigned by Zollino to 14q32. Kyphosis (HP:0002808) also reported.
• Juvenile osteoporosis / osteopenia (HP:0000939 / HP:0000938) — "less frequently observed" [verify]
• Arthritis (HP:0001369) — less frequent
• Celiac disease — less frequent [verify CURIE]
• Gastrointestinal symptoms / GERD / constipation — "affect many children" [verify]
• Café-au-lait spots (HP:0000957) — less frequent
• Lymphedema — "puffy hands and/or feet" (HP:0001004) — reported by MedlinePlus/GARD; frequency not quantified in the primary series
• Congenital malformations of heart, kidneys, urinary tract — "very rarely reported" [verify]. This is a discriminating negative: r(14) is not a multiple-congenital-anomaly syndrome in the usual sense.

3.8 Neuroimaging

Guideline [verify]: "Magnetic resonance imaging does not typically detect any specific changes." When abnormal: "mild brain atrophy, abnormalities of the corpus callosum, mild ventricular dilatation, hippocampus anomalies and structural alterations of the cerebellum."

HPO: HP:0002059 Cerebral atrophy · HP:0001274/HP:0002079 corpus callosum abnormality · HP:0002119 Ventriculomegaly · HP:0025100? hippocampal abnormality (verify) · HP:0001317 Abnormal cerebellum morphology.

3.9 Quality of life — the 2026 patient-centered model

SanInocencio C, et al. "Development of a patient-centered conceptual disease model in Ring 14 syndrome: a patient-centered model of lived experience." Qual Life Res 2026. PMID:41533279, DOI:10.1007/s11136-025-04140-5.

17 caregivers representing 12 patients; semi-structured interviews. The model spans patient domains (cognitive, physical, behavioral, social-emotional, QoL) and caregiver domains (mental health, family/social, medical care). Key finding [verify]:

"impacts listed under the patient quality of life domain as well as the caregiver domain are inadequately represented in the literature"

This is the single most important recent addition for QoL curation, and it is explicitly a critique of the existing literature's clinician-centric framing. No EQ-5D/SF-36/PROMIS data exist for r(14).

4. Genetic / Molecular Information

4.1 The lesion

There is no single causal gene. The lesion is the ring structure plus variable 14q32.33 hemizygosity.

Chromosome 14 (GRCh38): acrocentric, 107,043,718 bp. The p arm is heterochromatic/rDNA-bearing and gene-poor; the p-arm breakpoint (typically p11 or p13) is therefore usually phenotypically silent for coding content but is central to the position-effect hypothesis (§6).

Terminal 14q deletion sizes reported: - Zollino 2012 (n=27): 0.3–5 Mb in 21/27; complete ring in 6/27 [abstract-verbatim] - Zollino 2009 (n=20): 0.65–5 Mb in 14/20; complete ring in 6/20 - Meza-Espinoza 2024 (n=1): ~1.7 Mb, chr14:105,194,385–106,876,229 (GRCh38), 23 genes [verify] - Gardner et al. 2024 (PMID:38824650): "Ring Chromosome 14 with a Terminal 14q32.33 Deletion"

4.2 Genes in the commonly deleted 14q32.33 interval

Verified coordinates (Ensembl REST, GRCh38):

Other genes in the terminal ~2 Mb (for completeness; individually unvalidated for r(14) phenotype): INF2, ADSS1(ADSSL1), SIVA1, AKT1, ZBTB42, CEP170B, PLD4, AHNAK2, CDCA4, GPR132, JAG2, NUDT14, BRF1, PACS2, TEX22, MTA1, CRIP1/CRIP2, TMEM121, ELK2AP, ADAM6.

Assay-relevant caution: AKT1 (14q32.33) and DICER1 (14q32.13) are cancer-relevant genes on this chromosome, but no increased neoplasia risk has been reported in r(14) syndrome and DICER1 lies well proximal to typical ring 14 deletions. Do not curate a tumor-predisposition claim.

4.3 The 40 chromosome-14 epilepsy genes (Vaisfeld 2021)

Vaisfeld et al. catalogued 40 epilepsy-related genes across chromosome 14 and analyzed seven in detail [verify]:

Crucially, all of these except PACS2 lie outside the deleted segment in ring 14 — they are present in two copies. That is precisely the enigma. Vaisfeld's conclusion [verify]:

"With the exception of FOXG1 and PACS2, none of the genes … has a clear and unquestionable epileptogenic potential."

4.4 Zollino's regional assignment (the standing genotype–phenotype model)

From the 2012 abstract [abstract-verbatim]:

"Based on literature review of linear deletions, affecting either the proximal or the distal 14q region, we could deduce that retinal abnormalities and epilepsy map within the proximal 14q11.2-q12 region. Because this region is preserved in all patients with ring 14, we speculate that genes residing in the proximal 14q interval are disregulated through heterochromatinization spreading from the adjacent short arm of the chromosome. Behavior disorders and susceptibility to infections can be assigned to the 14q32 region, haploinsufficiency being the most likely underlying mechanism."

This yields a two-mechanism model that should structure the dismech pathophysiology graph:

• Proximal 14q11.2–q12 (present in 2 copies) → dysregulated by position effect / heterochromatin spreading → epilepsy + retinal abnormalities. Candidate effector: FOXG1.
• Distal 14q32.33 (hemizygous) → classical haploinsufficiency → behavior disorders + infection susceptibility (IGH), possibly seizures via PACS2.

Note that Zollino 2009 (PMID:19441122) placed microcephaly and intellectual disability with the proximal group as well; scoliosis with 14q32.

4.5 Variant classification, allele frequency, origin

• Classification: Not an ACMG sequence-variant question. Reported as a pathogenic structural/cytogenetic abnormality; ClinVar/DECIPHER/ECARUCA/dbVar carry the CNV component (terminal 14q32.33 loss) but not the ring topology.
• Allele frequency: Not applicable. Terminal 14q32.33 deletions of this size are absent from gnomAD-SV control frequencies at any appreciable level.
• Origin: Germline, de novo, in the overwhelming majority. Deleted rings 75% paternal / 25% maternal (Zollino 2012) [abstract-verbatim]. Somatic mosaicism for ring loss is universal (§6) but is a secondary somatic event on a germline lesion.
• Functional consequence: Combined loss of function (hemizygosity, 14q32.33) and loss of normal regulation (position effect on 14q proximal — a qualitative, not quantitative, change).

dismech schema note. For the 14q32.33 genes, GeneticContext.functional_impact_category: LOSS_OF_FUNCTION with allele_type structural/CNV. For the proximal 14q dysregulation, the correct slot is Descriptor.modifier — and because the claim is that the locus is "no longer under normal regulatory control" rather than merely running low, LOSS_OF_FUNCTION (qualitative, unbound) is defensible over DECREASED. Make that trade explicitly per CLAUDE.md guidance.

4.6 Modifier genes

None validated. Candidate modifiers, all hypothesis-level: deletion size (determines PACS2 / IGH status); presence of cryptic proximal duplication; degree of somatic ring instability; parental origin (paternal skew — imprinting at DLK1-MEG3 14q32.2 is a theoretical but unproven contributor, and UPD(14) was excluded in all Zollino cases).

4.7 Epigenetics

This is where the modern mechanistic action is.

• Heterochromatin spreading / telomere position effect (TPE): ring formation juxtaposes the acrocentric p-arm heterochromatin (rDNA, satellite) with proximal 14q euchromatin, and removes the native 14q telomere. Guideline [verify]: ring formation may cause "perturbation of the epigenetic state of specific genes along chromosome 14," with "heterochromatin spreading and possible repositioning" as proposed mechanisms.
• Empirical support: Ferreira et al., J Appl Genet 2015 — "Position effect modifying gene expression in a patient with ring chromosome 14." Guideline notes recent studies "confirmed gene expression changes in patients with r(14) syndrome" [verify]. Analogous TPE evidence exists for ring 17 (PMC3892072) and transcriptome-level evidence for ring 20 (PMID:33207017).
• Non-coding RNA gap (Vaisfeld 2021) [verify]: "there is essentially no literature concerning the possible role of untranslated RNAs in the r(14) syndrome," and the 14q32 region "contains the largest cluster of microRNAs in the entire human genome" — the imprinted DLK1-DIO3 miRNA mega-cluster at 14q32.2. This is a first-class KNOWLEDGE_GAP discussion for the entry.
• TADs: the active NCT06813469 study (below) is testing whether ring formation disrupts topologically associating domains.

4.8 Chromosomal abnormality summary

• Constitutional ring chromosome 14, replacing one normal chromosome 14
• Typical ISCN: 46,XX,r(14)(p11q32.33) / 46,XY,r(14)(p13q32.33)
• Frequently accompanied in vivo by a secondary somatic mosaic: 45,XX,-14 / 46,XX,r(14) / 46,XX,r(14)x2 / 47,XX,r(14),+r(14) etc.
• Detected by karyotype (ring topology) + array CGH/SNP array (deletion extent). Array alone will miss a complete ring and will misclassify a deleted ring as a linear terminal deletion — a diagnostically consequential error.

5. Environmental Information

Environmental factors: None causally implicated. Ring chromosome formation is a de novo mitotic/meiotic accident; no toxin, radiation, pollutant, or occupational exposure has been linked to constitutional r(14).

Lifestyle factors: None causally implicated in disease occurrence. Post-diagnosis, nutrition is a major modifying exposure — anorexia/malnutrition is a named prognostic determinant, and vitamin D insufficiency is prevalent enough that the guideline recommends double-RDA supplementation (≈800–1,000 IU/day) prophylactically [verify].

Infectious agents: Not causal. But respiratory pathogens are a first-class disease-modifying exposure — they act on an established immune lesion and represent the main adult mortality mechanism. This is the one environmental entry that genuinely earns influences_mechanisms in the dismech pathograph:

environmental:
- name: Recurrent respiratory pathogen exposure
  influences_mechanisms:
  - target: Impaired humoral immunity
    environmental_effect: EXACERBATES
    causal_link_type: DIRECT

A second, iatrogenic exposure is documented: chronic aspiration of cannabis oil used for seizure control caused lipoid pneumonia in a 4-year-old with ring chromosome 14 (Hanzal et al., Chest 2025, PMID:40348517) [verify] — a real adverse-event signal given how commonly CBD oil is used in this population.

ECTO binding candidates (all require OAK verification against cache/ecto/; per the dismech-terms rule, no term beats a bad one): exposure to respiratory pathogens; oral exposure to cannabidiol. If ECTO has nothing precise, leave unbound with a review_notes: waiver recording the search.

6. Mechanism / Pathophysiology

This is the section that should carry the entry's mechanistic weight. The causal architecture has four partially independent arms, and the field explicitly does not know which dominates.

6.1 Upstream initiating event

Ring chromosome 14 formation — two breakpoints (14p + 14q), end-to-end fusion, telomere loss.

GO: GO:0032200 telomere organization · GO:0006281 DNA repair · GO:0000724 double-strand break repair via homologous recombination · GO:0051276 chromosome organization.

6.2 Arm A — Position effect / heterochromatin spreading (→ epilepsy, retinal phenotype)

Causal chain:

ring formation
  → loss of 14q telomere + juxtaposition of 14p acrocentric heterochromatin to proximal 14q
  → heterochromatin spreading / altered nuclear repositioning (telomere position effect)
  → transcriptional silencing/dysregulation of proximal 14q11.2–q12 genes (2 copies present)
  → reduced FOXG1 (and neighbors) function in developing forebrain
  → abnormal cortical neuron differentiation and excitation/inhibition imbalance
  → early-onset drug-resistant focal epilepsy; microcephaly; retinal pigmentary abnormality

This arm explains the central dissociation: linear 14q deletions of matched size cause neither refractory epilepsy nor retinal changes, because they leave the p-arm/telomere relationship intact.

GO: GO:0031507 heterochromatin formation · GO:0016458 gene silencing · GO:0006357 regulation of transcription by RNA Pol II · GO:0007399 nervous system development · GO:0021895 cerebral cortex neuron differentiation · GO:0060384? — prefer GO:0050767 regulation of neurogenesis. CL: CL:0000540 neuron · CL:0000598 pyramidal neuron · CL:0000617 GABAergic neuron · CL:0000679 glutamatergic neuron · CL:0011005? (verify) · CL:0002586 retinal pigment epithelial cell. UBERON: UBERON:0000955 brain · UBERON:0000956 cerebral cortex · UBERON:0002421 hippocampal formation · UBERON:0000966 retina.

biological_scale: — the heterochromatin/transcription nodes are MOLECULAR; neuron differentiation is CELLULAR; epilepsy is ORGANISM.

6.3 Arm B — Ring mitotic instability and dynamic mosaicism (→ growth failure, possible epileptogenic focus)

Rings are structurally unstable. Sister chromatid exchange within a ring generates dicentric and interlocked rings; anaphase bridging and lagging generate ring loss and micronuclei.

Vaisfeld 2021 [verify]:

"Sister chromatid exchanges occurring during mitosis can result in the generation of dicentric or interlocked rings, or lead to ring chromosome loss, creating a mosaic of cells with different functional properties."

And, critically for tissue-specificity:

the proportion of cells with complete ring loss "is known to be around 20% in peripheral blood cells" — but "it could be higher in areas of the brain contributing to a potential epileptogenic focus."

Directly measured instability (Meza-Espinoza et al., Mol Cytogenet 2024, PMID:39020403) [verify]: - 30/243 cells (12.3%) monosomic for 14 (ring lost) - 15/243 cells (6.2%) with three signals (duplicated/dicentric ring) - 27/305 (9%) interphase cells with micronuclei; FISH confirmed r(14) inside 21/21 micronuclei tested - Authors: "we were able to verify an instability of the r(14) chromosome, mainly involving anaphasic lags and its exclusion from the nucleus in the form of a micronucleus."

The guideline's counterpoint on the diagnostic side [verify]: in blood, "at least 85–90%" of cells harbor the ring, and aneuploid fractions are "usually below the sensitivity of a CGH-array."

Kosztolányi's "ring syndrome": growth failure as the near-universal, chromosome-independent consequence of ring instability ("dynamic mosaicism"), because mosaic monosomic cells have low viability and high death rate. Contemporary opinion has partly shifted toward hemizygous gene loss as the driver of malformations, with dynamic mosaicism retained principally for growth failure.

ring instability
  → anaphase lag / bridge → micronucleus formation → ring loss
  → mosaic monosomy 14 in a subset of somatic cells
  → cell-cycle arrest / apoptosis / reduced proliferative output
  → generalized growth failure, short stature, postnatal microcephaly
  → (hypothesized) locally high monosomic fraction in cortex → epileptogenic focus

GO: GO:0007059 chromosome segregation · GO:0140014 mitotic nuclear division · GO:0007094 mitotic spindle assembly checkpoint signaling · GO:0006915 apoptotic process · GO:0090398 cellular senescence · GO:0008283 cell population proliferation.

6.4 Arm C — 14q32.33 haploinsufficiency (→ immune, behavior, ?seizures)

terminal 14q32.33 deletion (0.3–5 Mb)
  → hemizygosity of IGH constant-region locus (chr14:~105.6–106.9 Mb)
  → reduced/skewed immunoglobulin heavy-chain repertoire
  → impaired humoral immunity (esp. IgA)
  → recurrent upper-airway infection → severe pneumonia → adult mortality

  → (when deletion >1.65 Mb) hemizygosity of PACS2
  → possible minimally penetrant epileptogenic effect, "enhanced by the formation of the ring"

Vaisfeld on PACS2 [verify]: "it may be worth exploring whether haploinsufficiency has a minimally penetrant epileptogenic effect, which is enhanced by the formation of the ring." This is an explicit two-hit / synergy hypothesis and should be curated as a mechanistic_hypotheses group with status: EMERGING, with the relevant downstream edges opting in via hypothesis_groups.

GO: GO:0002377 immunoglobulin production · GO:0006959 humoral immune response · GO:0016064 immunoglobulin mediated immune response · GO:0002250 adaptive immune response. CL: CL:0000236 B cell · CL:0000786 plasma cell · CL:0000084 T cell. UBERON: UBERON:0002405 immune system · UBERON:0001004 respiratory system · UBERON:0002048 lung.

6.5 Arm D — Aberrant IgG N-glycosylation (2026, newest)

Messina A, et al. "IgG Glycosylation Analysis in Patients with Ring14 Syndrome Unveils Novel Pathomechanisms and New Therapy Perspectives." Biomolecules 2026;16(6):760. PMID:42352229, DOI:10.3390/biom16060760 (preprint: doi:10.20944/preprints202604.0844.v1)

Six RC14 patients vs. age-matched controls; UHPLC-FLR + high-resolution ESI-MS [verify]: - Decreased galactosylation and sialylation, "resembling pro-inflammatory patterns observed in autoimmune diseases" - Increases in the afucosylated species A2G1 and the agalactosylated structures FA2 and FA2B; increases in bisected and afucosylated N-glycans - ANOVA identified seven N-glycans with significant intensity differences - Changes appeared selective to IgG - Interpretation: alterations "might enhance the pro-inflammatory IgG structures while decreasing the anti-inflammatory ones"

The mechanistic puzzle the authors themselves raise [verify]: "No genes encoding galactosyltransferases or sialyltransferases are located on chromosome 14." So the glycosylation phenotype cannot be explained by simple hemizygosity — it is either a trans consequence of ring-driven transcriptional dysregulation or a secondary inflammatory-state readout. Curate this explicitly as a KNOWLEDGE_GAP.

Therapeutic signal: Patient 1 on IVIG showed "a reduction in seizures from 5–6/week to one/week," causality uncertain [verify]. Authors propose IVIG and/or monoclonal antibodies to modulate the inflammatory response.

GO: GO:0006487 protein N-linked glycosylation · GO:0006486 protein glycosylation · GO:0006954 inflammatory response · GO:0002455? humoral immune response mediated by circulating immunoglobulin. CHEBI: N-glycan / oligosaccharide terms — verify before binding.

6.6 What is not known

• No proteomics, metabolomics, or lipidomics studies of r(14) exist beyond the IgG glycan work.
• No single-cell or spatial transcriptomics.
• No CRISPR/RNAi functional screen.
• Transcriptomics is limited to small position-effect studies (Ferreira 2015) and the ring 20 analogue (PMID:33207017).
• The MD-RING study (NCT06813469) is the first systematic multi-omic/long-read effort — see §12/§15.

7. Anatomical Structures Affected

Organ level

Primary: - Brain / central nervous system — UBERON:0000955. Cerebral cortex (UBERON:0000956), hippocampal formation (UBERON:0002421), corpus callosum (UBERON:0002336), cerebellum (UBERON:0002037), lateral ventricles (UBERON:0002285). - Eye / retina — UBERON:0000970 eye; UBERON:0000966 retina; UBERON:0004864? macula lutea (verify); UBERON:0000941 optic nerve; UBERON:0001769 iris; UBERON:0000965 lens of camera-type eye.

Secondary / systemic: - Immune system — UBERON:0002405; respiratory system — UBERON:0001004; lung — UBERON:0002048 - Digestive system — UBERON:0001007 (feeding difficulty, dysphagia, GERD, celiac disease) - Musculoskeletal: vertebral column — UBERON:0001130 (scoliosis, kyphosis); skeleton — UBERON:0004288 (osteopenia/osteoporosis); musculature — UBERON:0001015 (hypotonia) - Craniofacial skeleton — UBERON:0010363? / UBERON:0001474 bone element; dentition — UBERON:0003672? (verify) - Lymphatic system — UBERON:0006558? / UBERON:0002465 lymphoid system (lymphedema of hands/feet)

Body systems: nervous, visual/sensory, immune, respiratory, digestive, musculoskeletal, lymphatic. Notably spared: cardiovascular and renal/urinary — congenital malformations of heart, kidney, and urinary tract are "very rarely reported."

Tissue and cell level

Subcellular level

• Nucleus — GO:0005634; chromosome / centromeric region — GO:0000775; heterochromatin — GO:0000792; nuclear periphery/lamina — GO:0005652? nuclear lamina (verify) — relevant to repositioning
• Micronucleus — GO:0097604? (verify; may require free text) — the direct cytological readout of ring loss
• Mitotic spindle — GO:0072686
• Golgi apparatus — GO:0005794 (site of IgG N-glycan maturation)

Localization / lateralization

Brain involvement is bilateral and diffuse; EEG shows generalized slow background with multifocal spikes and a posterior/occipital predominance of complex spike-and-wave. Retinal involvement is bilateral. Facial asymmetry ("long and sometimes asymmetrical face") is a described but minor asymmetric feature. Scoliosis is by definition an asymmetric axial deformity.

8. Temporal Development

Onset

• Lesion: congenital — de novo, arising in gametogenesis or very early embryogenesis.
• Growth restriction: may begin prenatally (IUGR reported), but microcephaly is characteristically postnatal-onset — a useful discriminator.
• Epilepsy: "usually … in the first months of life"; infantile onset is the annotated HPO onset (HP:0003593). One series reported r(14) seizure onset at 3–24 months, after developmental delay was already apparent (PMID:41087847) [verify].
• Developmental delay: recognized in infancy, frequently before seizure onset.
• Onset pattern: chronic/insidious for the developmental phenotype; the epilepsy onset can be abrupt.

Progression

The disease is non-progressive at the level of the underlying lesion (GARD explicitly: "Condition is non-progressive"), but the clinical course has three distinguishable phases:

Progression rate: variable, driven by seizure burden. Course pattern: episodic seizures (with clusters) on a stable, non-degenerative developmental baseline. Duration: chronic, lifelong.

Patterns

• Remission: no spontaneous remission of the disorder. Seizure amelioration with age is real but partial. A critical caveat from the guideline [verify]: "Interrupting effective antiepileptic therapies when the symptomatology appears less severe could lead to the return of seizures that may even result no longer responsive to previously effective treatments." — i.e. apparent improvement is not a license to withdraw ASMs.
• Critical periods / intervention windows:
• First 5 years — aggressive seizure control to protect the developmental trajectory (the encephalopathic-effect claim)
• Infancy onward — early physical therapy "to reduce hypotonic complications (such as scoliosis) due to the reduced muscle tone" [verify]
• Throughout — nutritional support before malnutrition is established
• Adulthood — infection prophylaxis/surveillance, the dominant mortality risk

9. Inheritance and Population

Epidemiology

For dismech prevalence::

prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_per_100000: 0.1        # upper bound; <1 per 1,000,000 = <0.1 per 100,000
  notes: >-
    Orphanet worldwide point-prevalence class <1/1,000,000. Approximately 80-100
    cases reported in the literature since 1971; exact prevalence unknown and
    almost certainly underascertained because array-only testing misses the ring.

Ascertainment caveat worth curating: because chromosomal microarray has largely displaced karyotyping as a first-tier test, a deleted ring 14 is now readily misreported as a linear 14q terminal deletion, and a complete ring 14 (no copy-number change, ~22% of cases) is invisible to array entirely. Reported prevalence is therefore a floor.

Inheritance

• Pattern: Sporadic / de novo, not inherited (HP:0003745 Sporadic). ORDO annotates inheritance as "Not applicable; Unknown."
• MedlinePlus: "Ring chromosome 14 syndrome is typically not inherited. A ring chromosome usually occurs as a random event during the formation of reproductive cells or during early embryonic development." Rare familial transmission has been documented but is exceptional.
• Penetrance: complete for the ring carrier state (all reported ring 14 individuals are affected).
• Expressivity: variable — driven by deletion size, ring instability, and cryptic duplications.
• Anticipation: not applicable (no repeat expansion; transmission is essentially never observed).
• Germline mosaicism: not reported; empiric recurrence risk to parents is very low but a de novo event cannot be formally excluded from a gonadal-mosaicism origin.
• Somatic mosaicism: universal — for ring loss/duplication (see §6.3). Distinguish carefully from constitutional mosaicism for the ring itself, which is occasionally reported.
• Founder effects: none. Consanguinity: no role. Carrier frequency: not applicable.

Population demographics

• Ethnic/geographic: no predilection reported; cases described worldwide (Italy, USA, Mexico, Russia, China, Turkey, Bulgaria, Estonia in the recent literature).
• Sex ratio: not established. A general ring-chromosome cohort (Murry et al., Genes 2025, PMID:40725393; 40 constitutional rings over 37 years) noted "a preponderance of pediatric-aged females at first ascertainment" [verify] — but this is an ascertainment observation across all rings, not an r(14)-specific sex ratio, and should not be curated as one. A 2025 Chinese series of 9 ring-chromosome children was 6F:3M overall (PMID:41087847), again too small and not r(14)-specific.
• Age distribution: diagnosis typically in infancy/early childhood following seizure onset and developmental delay; GARD notes symptom recognition often ages 2–11 y. Adults are described but the adult natural history is poorly characterized.

10. Diagnostics

The diagnostic algorithm (2017 task-force consensus)

The guideline's central diagnostic recommendation has two halves, and the second is the one most often missed [verify]:

1. Array-CGH as the first diagnostic step for a child with "neuro-psychological alterations and drug-resistant epilepsy."
2. "All subject for whom a 14q terminal deletion is identified should be addressed to a standard karyotype to assess the presence of the ring."

Plus a sensitivity requirement: "The analysis of at least 30 metaphases is necessary for a >95% chance of detecting a r(14) chromosome that occurs in at least 80% of cells."

Genetic testing

Baseline clinical evaluation (guideline) [verify]

"cerebral MR, EEG, heart and abdomen US, oculistic and audiologic evaluation, neuropsychological assessment."

Clinical / laboratory / imaging tests

• EEG (essential; also a severity marker correlating negatively with cognition) — LOINC/NCIT term needed
• Brain MRI — usually normal or with nonspecific mild atrophy/callosal/ventricular/hippocampal/cerebellar changes
• Ophthalmologic exam incl. dilated fundoscopy and multimodal imaging (OCT, fundus autofluorescence, near-infrared reflectance — Vasconcelos 2019 showed macular yellow dots only on multimodal imaging)
• Immunological workup: quantitative immunoglobulins (IgG, IgA, IgM), IgG subclasses, specific antibody responses — annually per guideline
• Nutritional/growth: anthropometrics, vitamin D, swallow study when aspiration suspected
• Skeletal: spine radiographs for scoliosis; DXA for osteopenia
• Cytogenetic instability assays (research/specialist): micronucleus assay + FISH (Meza-Espinoza 2024)
• Emerging biomarker (research only): IgG N-glycan profile by UHPLC-FLR/ESI-MS — decreased galactosylation and sialylation (Messina 2026). Not validated; no PPV/NPV data.

No validated biochemical biomarker, no newborn-screening analyte, no FDA-listed biomarker exists.

Diagnostic criteria and differential

There are no formal consensus diagnostic criteria (no DSM/ICD-style rule set). Diagnosis is cytogenetic.

Differential diagnosis:

Screening

• Newborn screening: not applicable — no biochemical marker.
• Carrier screening: not applicable — de novo.
• Cascade screening: not indicated (parental karyotype is for counseling reassurance, not cascade testing).
• Prenatal: karyotype ± CMA on CVS/amniocentesis will detect a ring 14; NIPT/cfDNA will not reliably detect it (small terminal CNV; no ring topology information). Prenatal detection is generally incidental or follows an abnormal ultrasound (IUGR).

11. Outcome / Prognosis

Survival and mortality

The honest curation answer is "not established." Guideline [verify]:

"A precise prognosis in terms of expected lifespan in individuals with r(14) syndrome has yet to be established." "Prognosis should be estimated individually and depends primarily on comorbidities and medical complications." "The epileptic burden, infectious complications and nutritional deficiencies should be considered as major determinants."

• No 5-year or 10-year survival figures, no life-expectancy estimate, no mortality rate exists in the literature. Do not manufacture one.
• Leading cause of adult death: infection. "Infections are one of the worse prognostic factors and the main cause of death in adulthood" [verify].
• Survival into adulthood is clearly attainable — the Meza-Espinoza 2024 index case was 21 years old.
• SUDEP risk is not quantified for r(14) but is a reasonable concern given lifelong drug-resistant epilepsy; do not curate a numeric estimate.

Morbidity and function

• Intellectual disability, moderate to severe, in essentially all patients — the dominant long-term functional determinant alongside epilepsy.
• Many patients are nonverbal; the guideline's management emphasis on preserving communication reflects this.
• Ambulation: achieved late (2–3 years) in most; some never walk.
• Lifelong dependence for activities of daily living is the norm.
• No EQ-5D, SF-36, PROMIS, or disease-specific validated QoL instrument has been applied. The SanInocencio 2026 conceptual disease model (PMID:41533279) is the first systematic characterization of lived experience and is explicitly the foundation for a future COA/PRO instrument — cite it as the QoL source of record and note the absence of quantitative instruments as a gap.

Complications

Recurrent/severe respiratory infection · aspiration pneumonia (including iatrogenic lipoid pneumonia from oil-based CBD, PMID:40348517) · status epilepticus (~50%) · developmental regression during periods of intense epileptic activity · malnutrition requiring enteral feeding · scoliosis · juvenile osteoporosis/osteopenia with fracture risk · visual impairment in a minority · sleep disorder · celiac disease.

Recovery potential

None in the sense of cure. Meaningful, treatment-attributable improvement is possible in seizure frequency (with ASMs, ketogenic diet, VNS, CBD), nutritional status (enteral feeding), and motor complications (early physiotherapy). The developmental disability itself is not reversible with current therapy.

Prognostic factors

1. Seizure burden and EEG severity in the first years — negatively correlated with cognitive development (Giovannini 2013)
2. Infection frequency/severity — the adult mortality driver
3. Nutritional status — named guideline determinant
4. Deletion size — larger terminal deletions include PACS2 and more of IGH; the ≥650 kb threshold marks the recognizable facial gestalt
5. Degree of ring instability — biologically plausible, clinically unvalidated

No prognostic biomarker is validated. The IgG glycan profile is the only candidate on the horizon.

12. Treatment

There is no disease-modifying or curative therapy. Management is symptomatic, multidisciplinary, and guideline-directed.

12.1 Antiseizure pharmacotherapy

Guideline [verify]: "Antiepileptic drugs are frequently used: barbiturates (in the first months of life), valproic acid, carbamazepine, topiramate, vigabatrin, clobazam and levetiracetam." And: "About half of patients with r(14) syndrome show drug resistance, while in the remaining half seizure control is variable."

Explicit management warning to curate [verify]: do not withdraw an effective ASM during a quiescent phase — "Interrupting effective antiepileptic therapies when the symptomatology appears less severe could lead to the return of seizures that may even result no longer responsive to previously effective treatments."

12.2 Cannabidiol

Guideline preliminary data [verify]: seizure frequency reduced with an "adequate safety profile," dosing "2–5 mg/Kg per day, up-titrated until intolerance or to a maximum of 20–25 mg/kg per day" — i.e. the Epidiolex regimen. Note that CBD has RCT-grade evidence and FDA/EMA approval in Dravet and Lennox–Gastaut, not in r(14); its use here is extrapolation plus small-series experience.

Safety signal: oil-based CBD aspiration caused lipoid pneumonia in a 4-year-old with ring chromosome 14 (PMID:40348517) — relevant given the high baseline aspiration risk in this population.

therapeutic_modality: SMALL_MOLECULE; therapeutic_agent: cannabidiol (verify CHEBI CURIE).

12.3 Non-pharmacological seizure therapy

• Ketogenic diet — "may be taken in consideration for the therapeutic strategy" [verify]. treatment_term: NCIT:C15447 Dietary Intervention; therapeutic_modality: BEHAVIORAL.
• Vagus nerve stimulation — same recommendation strength. therapeutic_modality: DEVICE; NCIT term for vagus nerve stimulation (verify).
• Epilepsy surgery — not applicable; the epilepsy is multifocal/diffuse with no resectable focus.

12.4 Immunological / experimental

• IVIG — one RC14 patient on IVIG showed seizure reduction from 5–6/week to ~1/week (Messina 2026) [verify]; causality explicitly uncertain, n=1. The authors propose IVIG and/or monoclonal antibodies to modulate inflammation. Curate as EMERGING hypothesis with supports: PARTIAL, not as an established treatment.
• Antibiotic prophylaxis / immunization — implied by the annual immunology follow-up recommendation; specific regimens are not specified in the guideline.

12.5 Supportive, nutritional, rehabilitative

Follow-up cadence (guideline) [verify]: "Immunologist, once per year; child Neurologist/Neurologist, as needed; Ophthalmologist, as needed; Gastroenterologist/Nutritionist, as needed."

12.6 Advanced therapeutics — none available

• Gene therapy / gene editing: not applicable in current form — the lesion spans megabases and, per the position-effect model, involves chromosome architecture rather than a single gene.
• RNA-based therapy (ASO/siRNA): no target established.
• Cell therapy: none clinically. But see the "chromosome therapy" concept in §15 — reprogramming-mediated ring correction is the only conceptual disease-modifying route ever proposed for ring disorders, and it is preclinical.
• Pharmacogenomics: no r(14)-specific PGx. Standard CPIC guidance applies (notably HLA-B*15:02/HLA-A*31:01 for carbamazepine, CYP2C9 for phenytoin/valproate considerations, POLG contraindication screening before valproate in unexplained epileptic encephalopathy). These are population-standard, not disease-specific.

12.7 Clinical trials

Brief summary [verify]: "The MD-RING study investigates how position effects and TAD alterations may cause ring chromosome 14 syndrome. Researchers aim to clarify genetic-to-clinical relationships, establish resources for ring syndrome research, and ultimately enhance family counseling, patient management, and identify potential therapeutic approaches."

No interventional therapeutic trial specific to ring chromosome 14 has ever been conducted.

13. Prevention

Primary prevention: not possible. A de novo structural chromosomal event with no known modifiable risk factor. There is nothing to modify — no vaccination, no exposure reduction, no behavioral intervention that alters occurrence.

Secondary prevention (early detection): - No population screening program exists or is justifiable at this prevalence. - The actionable secondary-prevention message is diagnostic: karyotype every child in whom a 14q terminal deletion is found on array, and karyotype (≥30 metaphases) children with early-onset drug-resistant epilepsy + developmental delay + microcephaly + retinal changes whose gene panel is negative. Earlier diagnosis enables earlier immunological, ophthalmologic, and nutritional surveillance. - Prenatal/reproductive: karyotype ± CMA on CVS/amniocentesis detects a ring 14. PGT is theoretically available but essentially never indicated given the de novo origin and negligible recurrence risk. Prenatal testing in a subsequent pregnancy may be offered for reassurance.

Tertiary prevention (preventing complications) — this is where nearly all the actionable prevention lives:

Genetic counseling: the core message is (1) sporadic, de novo origin; (2) recurrence risk to the parents is very low (empiric, with the caveat that germline mosaicism cannot be formally excluded); (3) parental karyotypes are appropriate to exclude the rare familial ring; (4) recurrence risk for the affected individual's own offspring is not a practical question given the severity of the phenotype. NCIT:C15240 Genetic Counseling.

Public health / environmental interventions: not applicable.

14. Other Species / Natural Disease

Direct orthologue disease

None. There is no naturally occurring "ring chromosome 14 syndrome" in any non-human species, and there cannot be a direct orthologue: human chromosome 14 is a synteny construct that maps onto multiple chromosomes in mouse (principally Mmu 12 and Mmu 14) and other mammals. The disease concept is human-chromosome-specific.

• NCBI Taxonomy: NCBITaxon:9606 Homo sapiens — the only species in which this disease entity is defined.
• VBO breed terms: not applicable.

Comparative biology that is relevant

• Ring chromosomes as a class occur in other species. Constitutional and radiation-induced ring chromosomes are documented in mouse, dog, cattle, and horse cytogenetics, and ring-chromosome instability (anaphase bridging, sister-chromatid-exchange–driven ring loss) is a conserved mitotic phenomenon, not a human peculiarity. This makes the instability arm of the mechanism (§6.3) comparatively tractable even though the disease is not.
• OMIA: no ring chromosome 14 entry. Searching OMIA for ring-chromosome entries is worthwhile for the general instability biology but will not yield a disease analogue.
• Gene orthologues (for arm-specific modeling rather than for the syndrome): Foxg1 (mouse, NCBI Gene 15228), Pacs2 (mouse), Chd8 (mouse) — all have well-characterized mouse models with neurodevelopmental phenotypes.
• Evolutionary conservation: telomere position effect and heterochromatin spreading are deeply conserved (classic Drosophila position-effect variegation, S. cerevisiae subtelomeric silencing), which is the strongest cross-species support for the position-effect hypothesis — though as an analogy, not as evidence about r(14) itself.

Transmission

Not applicable. Non-infectious, non-zoonotic, no cross-species susceptibility.

15. Model Organisms

The core problem

There is no animal model of ring chromosome 14 syndrome, and building one is not straightforward. A mouse cannot carry a ring human chromosome 14; engineering a ring from the syntenic mouse regions would not reproduce either the gene content or the p-arm heterochromatin juxtaposition that the position-effect model depends on. Vaisfeld et al. close by calling for work "especially addressing the expression and functional consequences of candidate pathogenic genes and the role of epigenetic mechanisms in simplified model systems" [verify] — an explicit acknowledgment that no faithful whole-organism model exists.

For dismech, this belongs in a HUMAN_MODEL_MISMATCH discussion, not a generic KNOWLEDGE_GAP: model-system evidence exists for the component genes, but its translational validity to the ring-specific mechanism is precisely the open question.

15.1 Patient-derived cellular models (the workhorse)

15.2 The iPSC caveat that must be curated

Bershteyn M, Hayashi Y, Desachy G, et al. "Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells." Nature 2014;507(7490):99–103. PMID:24413397, DOI:10.1038/nature12923 — studied ring 13 and ring 17, not ring 14. Abstract [abstract-verbatim]:

"Ring chromosomes are structural aberrations commonly associated with birth defects, mental disabilities and growth retardation. Rings form after fusion of the long and short arms of a chromosome, and are sometimes associated with large terminal deletions. Owing to the severity of these large aberrations that can affect multiple contiguous genes, no possible therapeutic strategies for ring chromosome disorders have been proposed. During cell division, ring chromosomes can exhibit unstable behaviour leading to continuous production of aneuploid progeny with low viability and high cellular death rate. The overall consequences of this chromosomal instability have been largely unexplored in experimental model systems. Here we generated human induced pluripotent stem cells (iPSCs) from patient fibroblasts containing ring chromosomes with large deletions and found that reprogrammed cells lost the abnormal chromosome and duplicated the wild-type homologue through the compensatory uniparental disomy (UPD) mechanism. The karyotypically normal iPSCs with isodisomy for the corrected chromosome outgrew co-existing aneuploid populations, enabling rapid and efficient isolation of patient-derived iPSCs devoid of the original chromosomal aberration. Our results suggest a fundamentally different function for cellular reprogramming as a means of 'chromosome therapy' to reverse combined loss-of-function across many genes in cells with large-scale aberrations involving ring structures. In addition, our work provides an experimentally tractable human cellular system for studying mechanisms of chromosomal number control, which is of critical relevance to human development and disease."

The two-edged implication for r(14) modeling:

1. As therapy concept — "chromosome therapy": reprogramming purges the ring. Related work: Kim et al. (PMID:25482192), and PMID:27882407 on ring correction via iPSC reprogramming. Entirely preclinical; no route to correcting a whole organism.
2. As a modeling hazard — this is the point that matters for curation. iPSC lines derived from ring-chromosome patients spontaneously lose the ring and become karyotypically normal via compensatory UPD, and the corrected cells then outcompete the ring-bearing ones. Any r(14) iPSC model therefore requires continuous karyotypic surveillance, and an apparently "isogenic control" may in fact be the intended disease line that self-corrected. See also "Complex biology of constitutional ring chromosomes structure and (in)stability revealed by somatic cell reprogramming," Sci Rep 2021, doi:10.1038/s41598-021-83399-3.

In dismech experimental_models terms, a patient iPSC line for r(14) is at best PARTIALLY_RECAPITULATES with fidelity: LOW-to-MODERATE and a mandatory limitations field naming the compensatory-UPD self-correction.

15.3 Component-gene animal models (surrogate, not disease models)

These model candidate effector genes, not the syndrome. Each should be curated with an explicit limitation that the ring context is absent.

Phenotype recapitulation: none of these reproduces the r(14) syndrome. Foxg1 models capture microcephaly and seizure susceptibility but not the retinal phenotype, the immune phenotype, or the ring itself. Limitations to record: no model reproduces (a) ring topology and its instability, (b) the p-arm heterochromatin juxtaposition, (c) combined proximal position effect + distal haploinsufficiency, (d) the human IGH locus architecture.

15.4 Resources

MGI · IMPC · KOMP · IMSR · EMMA · MMRRC (mouse); ZFIN (zebrafish); FlyBase; SGD; Alliance of Genome Resources; Cellosaurus / Coriell / NIGMS Human Genetic Cell Repository (patient fibroblast and lymphoblastoid lines); Ring14 International biobank and clinical database (ring14.org) — the practical route to patient-derived material.

Appendix A — Core reference set for the dismech entry

Appendix B — Suggested mechanistic_hypotheses groups

Appendix C — Suggested discussions (knowledge gaps)

1. KNOWLEDGE_GAP — Why do ring 14 and size-matched linear 14q deletions diverge so sharply for epilepsy and retinal phenotype? attaches_to: pathophysiology#Ring chromosome 14 formation
2. KNOWLEDGE_GAP — No brain-tissue data exist to test whether mosaic monosomy 14 is enriched in cortex. attaches_to: pathophysiology#Mosaic monosomy 14
3. KNOWLEDGE_GAP — The 14q32 DLK1-DIO3 miRNA cluster is entirely unstudied in r(14).
4. KNOWLEDGE_GAP — No gene on chromosome 14 encodes a galactosyl- or sialyltransferase; the IgG glycan phenotype is mechanistically unexplained. attaches_to: pathophysiology#Aberrant IgG N-glycosylation
5. HUMAN_MODEL_MISMATCH — Patient-derived iPSCs spontaneously purge the ring via compensatory UPD, so the standard human cellular model self-corrects away the lesion it is meant to model. attaches_to: experimental_models#…
6. KNOWLEDGE_GAP — No life-expectancy, mortality-rate, or validated QoL-instrument data exist. attaches_to: clinical_burden#

Next step: the highest-value thing to do before touching kb/disorders/Ring_Chromosome_14.yaml is to cache the reference set — just fetch-reference PMID:22564756 PMID:24116895 PMID:33205446 PMID:39020403 PMID:42352229 PMID:41533279 (plus ORPHA:1440, which is already ingestible via the structured Orphanet source) — and confirm the 2017 guideline's PMID, since every management and frequency claim in §3, §10, §11, and §12 traces to it and I have not verified its PMID against PubMed. Want me to run that fetch and report which snippets survive verification?

Sources

• Guideline recommendations for diagnosis and clinical management of Ring14 syndrome — Orphanet J Rare Dis 2017 (PMC5387247)
• Zollino et al., The ring 14 syndrome, Eur J Med Genet 2012 — PMID 22564756
• Zollino et al., The ring 14 syndrome: clinical and molecular definition, 2009 — PMID 19441122
• Vaisfeld et al., Chromosome 14 deletions, rings, and epilepsy genes, Epilepsia 2021 — PMID 33205446 (full text PDF)
• Giovannini et al., Epilepsy in ring 14 syndrome, Epilepsia 2013 — PMID 24116895
• Meza-Espinoza et al., Chromosomal instability in ring chromosome 14 syndrome, Mol Cytogenet 2024 (PMC11256661)
• Messina et al., IgG Glycosylation Analysis in Ring14 Syndrome, Biomolecules 2026 (PMC13297435)
• SanInocencio et al., patient-centered conceptual disease model, Qual Life Res 2026 — PMID 41533279
• Bershteyn et al., Cell-autonomous correction of ring chromosomes in human iPSCs, Nature 2014 — PMID 24413397
• Vasconcelos et al., Multimodal imaging of ring 14 syndrome associated maculopathy — PMID 31755799
• Guilherme et al., Mechanisms of ring chromosome formation, ring instability and clinical consequences, BMC Med Genet 2011
• MedGen: Ring chromosome 14 (C2930916)
• MedlinePlus Genetics: Ring chromosome 14 syndrome
• GARD: Ring chromosome 14
• OMIM 616606
• ClinicalTrials.gov NCT06813469 — MD-RING
• Ring14 International clinical database
• Hanzal et al., Lipoid pneumonia following chronic aspiration of cannabis oil, Chest 2025 — PMID 40348517
• Ivanoff et al., Ring chromosome 14 syndrome: what the dentist should know, Folia Med 2023 — PMID 36855970
• Barbour et al., Population-based study of rare epilepsy incidence, Epilepsia 2024 — PMID 38795333

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:22579566 (1 mention) - Evolution of metabolic rate in a parasitic wasp: the role of limitation in intrinsic resources.
• shared terms: phenotype

Weighed against this report's own most characteristic terms: ring, verify, chromosome, syndrome, gene, guideline, deletion, epilepsy, seizure, patient, phenotype, terminal, disease, q32, instability, zollino, model, retinal, mechanism, human.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0014708 (2 mentions) - the report calls it "MONDO"; MONDO calls it ring chromosome 14
• HP:0000752 (1 mention) - the report calls it "large proportion of patients" [verify]"; HP calls it Hyperactivity**
• HP:0000733 (1 mention) - the report calls it "Frequent"; HP calls it Motor stereotypy
• HP:0002360 (1 mention) - the report calls it "Less frequent"; HP calls it Sleep disturbance
• HP:0002205 (1 mention) - the report calls it "Recurring features include … increased incidence of infections, particularly respiratory infections" [verify]"; HP calls it Recurrent respiratory infections**
• HP:0006532 (1 mention) - the report calls it "Spectrum "from recurrent upper airways infections to severe pneumonia" [verify]"; HP calls it Recurrent pneumonia**
• UBERON:0001007 (1 mention) - the report calls it "feeding difficulty, dysphagia, GERD, celiac disease"; UBERON calls it digestive system
• UBERON:0001130 (1 mention) - the report calls it "scoliosis, kyphosis"; UBERON calls it vertebral column
• UBERON:0004288 (1 mention) - the report calls it "osteopenia/osteoporosis"; UBERON calls it skeleton
• UBERON:0001015 (1 mention) - the report calls it "hypotonia"; UBERON calls it musculature
• GO:0005794 (1 mention) - the report calls it "site of IgG N-glycan maturation"; GO calls it Golgi apparatus
• NCIT:C121351 (1 mention) - the report calls it "implied by multidisciplinary model"; NCIT calls it Occupational Therapy
• NCIT:C15240 (2 mentions) - the report calls it "de novo, low recurrence risk"; NCIT calls it Genetic Counseling

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0016458 (obsolete gene silencing) (1 mention)
• GO:0006486 (obsolete protein glycosylation) (1 mention) - replaced by GO:0009101

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0000957 (1 mention) - the report calls it "Café-au-lait spots"; HP calls it Cafe-au-lait spot, and lists "Cafe-au-lait spots" among its other names
• HP:0001004 (1 mention) - the report calls it "Lymphedema — "puffy hands and/or feet"; HP calls it Lymphedema, and lists "Onset of lymphedema around puberty" among its other names
• CL:0002586 (2 mentions) - the report calls it "Retinal pigment epithelium"; CL calls it retinal pigment epithelial cell
• CL:0000188 (1 mention) - the report calls it "Skeletal muscle"; CL calls it cell of skeletal muscle, and lists "skeletal muscle cell" among its other names
• CL:0000057 (2 mentions) - the report calls it "Dermal fibroblasts", "Patient dermal fibroblasts"; CL calls it fibroblast
• NCBITaxon:7227 (1 mention) - the report calls it "D. melanogaster"; NCBITaxon calls it Drosophila melanogaster
• NCBITaxon:4932 (1 mention) - the report calls it "Yeast"; NCBITaxon calls it Saccharomyces cerevisiae, and lists "baker's yeast" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• ORPHA:1440 - called "Orphanet", "ORDO annotation"
• CL:0000057 - called "Dermal fibroblasts", "Patient dermal fibroblasts"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.